<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038777</url>
  </required_header>
  <id_info>
    <org_study_id>B1371005</org_study_id>
    <nct_id>NCT02038777</nct_id>
  </id_info>
  <brief_title>A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies</brief_title>
  <official_title>A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04449913 (Glasdegib), An Oral Hedgehog Inhibitor, Administered As A Single Agent In Japanese Patients With Select Hematologic Malignancies And In Combination With Intensive Chemotherapy, Low-dose Ara-c, Or Azacitidine In Patients With Acute Myeloid Leukemia Or High-risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center, Phase 1 study of PF-04449913 in Japanese patients.
      PF-04449913 will be administered orally as a single agent in patients with select advanced
      hematologic malignancies, or in combination with LDAC [Low-Dose Ara-C] or cytarabine and
      daunorubicin in previously untreated patients with AML [Acute Myeloid Leukemia] or high-risk
      MDS [Myelodysplastic Syndrome], or in combination with azacitidine in previously untreated
      patients with AML.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2014</start_date>
  <completion_date type="Anticipated">October 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>MTD was determined in monotherapy cohort. Then two combination cohorts (Combination Cohorts 1 and 2) were added to evaluate the safety of glasdegib administered with chemotherapies. Another combination cohort (Combination Cohort 3) was added to evaluate the safety of glasdegib administered with Azacitidine. Now, under amendment 5, Continuation Cohort which allows one Japanese patient enrolled from another trial in the same project.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First cycle Dose Limiting Toxicities</measure>
    <time_frame>28 days after first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum observed plasma concentration (Tmax)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration curve (AUC)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective disease response</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-related gene mutation (PD biomarkers)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detectable tumor Gli1 expression (PD Biomarkers)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>For Azacitidine Combination Cohort only</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Monotherapy Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-04449913 Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-04449913 in combination with low dose ARA-C (LDAC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azacitidine Combination Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-04449913 in combination with azacitidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuation Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-04449913 Monotherapy for one patient rolled-over from another trial in the same project.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04449913</intervention_name>
    <description>PF-04449913 administered orally and continuously in 28 day cycles.</description>
    <arm_group_label>Monotherapy Cohort</arm_group_label>
    <arm_group_label>Continuation Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04449913</intervention_name>
    <description>PF-04449913 administered orally and continuously in 28 day cycles.</description>
    <arm_group_label>Combination Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose ARA-C (LDAC)</intervention_name>
    <description>Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.</description>
    <arm_group_label>Combination Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04449913</intervention_name>
    <description>PF-04449913 administered orally and continuously in 28 day cycles.</description>
    <arm_group_label>Combination Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Daunorubicin given using 60 mg/m2 for 3-days.</description>
    <arm_group_label>Combination Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine 100 mg/m2 on days 1 through 7.</description>
    <arm_group_label>Combination Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04449913</intervention_name>
    <description>PF-04449913 administered orally and continuously in 28 day cycles.</description>
    <arm_group_label>Azacitidine Combination Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.</description>
    <arm_group_label>Azacitidine Combination Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with select advanced hematologic malignancies who are refractory, resistant
             or intolerant to prior therapies for monotherapy cohort.

          -  Patients with AML or High-Risk MDS who are newly diagnosed and previously untreated
             for combination cohort.

          -  Patients with AML who are newly diagnosed and previously untreated for azacitidine
             combination cohort.

          -  ECOG [Eastern Cooperative Oncology Group] performance status 0 to 2

          -  Adequate organ function

        Exclusion Criteria:

          -  Patients with active CNS disease

          -  Patient with active malignancy with the exception of basal cell carcinoma, non
             melanoma skin cancer, carcinoma in situ cervical

          -  Patient has an active, life threatening or clinically significant uncontrolled
             systemic infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Japanese Red Cross Nagoya First Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>453-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akita University Hospital</name>
      <address>
        <city>Akita</city>
        <zip>010-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1371005&amp;StudyName=A%20Study%20Of%20PF-04449913%20In%20Japanese%20Patients%20With%20Select%20Hematologic%20Malignancies</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2014</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematologic Malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

